International journal of hematologyHumansLymphomaLarge B-CellDiffuseFemale
Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.
Yui Chikagawa, Daiki Higashi, Satoomi Sakai, Hiroki Yoshino, Yuki Nukii, Hiroki Mura, Shunichiro Nakagawa, Shinya Yamada, Takeshi Yoroidaka, Tatsuya Imi, Yoshitaka Zaimoku, Hiroyuki Maruyama, Kohei Hosokawa, Go Aoki, Akiyo Yoshida
Published: 202610.1007/s12185-025-04091-0
Abstract
A 53-year-old woman experienced relapse of diffuse large B cell lymphoma (DLBCL) 16 years after achieving a first complete metabolic response (CMR). Despite initially being refractory to salvage chemotherapy, she achieved a second CMR and underwent u…
Preview only. Read the full abstract at the source